Assessing Elevance Health (ELV) Valuation Following Recent Share Price Momentum

Elevance Health (ELV) shares have edged higher over the past week, with investors looking closely at recent performance and valuation. The company continues to draw attention because of its sizable footprint in the health benefits industry.

See our latest analysis for Elevance Health.

After a choppy start to the year, Elevance Health’s share price has begun to regain some positive momentum, advancing over 5% in the last week as investors weigh recent results and the company’s earnings outlook. While the 1-year total shareholder return remains in negative territory, the recent pickup hints at improved sentiment and potential for a turnaround, especially given the company’s consistent revenue and net income growth.

If you’re interested in seeking out similar opportunities among healthcare leaders, discover more with our See the full list for free.

With shares trading below analyst price targets and steady growth in both revenue and net income, the question remains: is Elevance Health currently undervalued, or has the market already taken into account all the company’s future growth potential?

Most Popular Narrative: 12.3% Undervalued

Elevance Health’s most widely followed valuation narrative currently estimates fair value at $386, notably above the recent close of $338. This sets the stage for a debate around future growth potential and margin recovery in the face of industry headwinds.

Elevance's ongoing expansion of value-based care arrangements, particularly within behavioral health and oncology, and the scaling of risk-based contracts through its Carelon division, position the company to benefit from increased cost predictability, better care coordination, and reduced volatility in medical cost ratios. These factors support potential future margin expansion.

Read the complete narrative.

Want to know which bold cost-control strategies and margin projections underpin that fair value? There’s a surprising combination of recurrent service growth and anticipated operational leverage. See what’s driving the valuation and which key numbers might catch the market off guard.

Result: Fair Value of $386 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent cost pressures and uncertain regulatory changes could still threaten Elevance Health’s margin recovery and long-term earnings outlook.

Find out about the key risks to this Elevance Health narrative.

Build Your Own Elevance Health Narrative

If you want to take a different view or prefer hands-on analysis, it’s easy to review the numbers yourself and build a fresh perspective in minutes, Do it your way

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Elevance Health.

Looking for More Smart Investment Ideas?

Don't let great opportunities pass you by. Get ahead of the market and fuel your portfolio with fresh possibilities using these popular, hand-picked stock searches:

• Pinpoint undervalued companies with winning fundamentals by starting your search through these 922 undervalued stocks based on cash flows. See which names remain overlooked by the crowd.
• Capture tomorrow’s tech outperformers when you scan these 25 AI penny stocks, which are making waves in artificial intelligence and machine learning innovation.
• Lock in income and stability as you browse these 15 dividend stocks with yields > 3%. This selection features stocks with generous yields for those seeking reliable long-term returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com